Maria Lauda Tomasi

Cedars-Sinai Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

ARF GTPase protein 1 (GIT1) is a scaffold protein that is overexpressed in hepatocellular carcinoma (HCC) and colorectal cancer (CRC). GIT1 forms a complex with methionine adenosyltransferase 2B (MAT2B) that activates RAS-RAF-MEK-ERK signaling in HCC and CRC to enhance tumorigenicity. Here, we investigated in a proof-of-concept study whether a small molecule that disrupts GIT1-MAT2B interaction can be effective in HCC and CRC treatment. Since the GIT1 crystal structure is unavailable, we developed a molecular model and used computer-based drug discovery approach to screen for small molecules targeting the GIT1 ankyrin repeat domain, the region closest to where MAT2B interacts that is accessible. Of nine compounds tested, compound 3 (C3) selectively interacts with GIT1 and shows an anti-cancer effect in a GIT1-dependent manner. C3 is antiproliferative, induced apoptosis and G2/M cell cycle arrest while inhibiting colony formation and migration in liver and colon cancer cells. C3 lowered interaction between GIT1 and MAT2B, and with downstream effectors cRAF, MEK and ERK, lowering MEK activity and cyclin D1 expression. Unexpectedly, C3 stabilized GIT1 interaction with cyclin B1 while weakening cyclin B1’s interaction with components of the anaphase promoting complex, concomitant with sustained cyclin B1 expression and mitosis arrest. In mice, C3 administration was well tolerated and inhibited murine CRC growth and liver metastasis in immune competent mice and human CRC growth in the livers of nude mice. In conclusion, a small molecule inhibitor that disrupts GIT1’s normal interactome is a promising new approach to treating liver and colon cancers.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Background Colorectal liver metastasis (CRLM) occurs frequently in patients with colorectal cancer (CRC). Methionine adenosyltransferase (MAT) catalyzes the formation of S-adenosylmethionine, the principal methyl donor. MAT1A (encodes MATα1) is expressed mainly in normal adult liver, whereas MAT2A (encodes MATα2) is expressed in all extrahepatic tissues. MAT1A is a major defense against CRLM as loss of Mat1a sensitizes the liver to CRLM. In contrast, MAT2A is overexpressed in CRC and promotes oncogenicity. Here, we sought to determine if CRCs secrete MATα2 and if this influences CRLM. Methods Our study included human hepatocytes, human CRC cells, extracellular vesicle (EV) isolation, chromatin immunoprecipitation (ChIP), ChIP-seq, promoter activity assays, proliferation, migration, and invasion assays, western blotting, immunohistochemistry and immunofluorescence. We confirmed some of the findings using human hepatocyte spheroids, CRLM and normal liver tissue array, and plasma samples. Results CRCs secrete MATα2 in free but truncated form (MATα2-t) and intact within EVs (EV-MATα2). EV-MATα2 can be internalized by human hepatocytes and CRCs, found within the nucleus, which then binds to MAT1A and MAT2A promoters on ChIP to lower and increase MAT1A and MAT2A promoter activities, respectively. In human CRLM samples, hepatocytes in nontumor regions express lower MATα1 but higher MATα2 as compared to normal liver. Treating RKO cells with EVs released from RKO cells overexpressing MAT2A promoted cell proliferation, migration, and invasion. MATα2-t was detected at a higher level in media from colon, pancreatic, and prostate cancer cell lines than corresponding normal epithelial cells as well as in the plasma of CRC patients as compared to healthy controls. RKO cells treated with MATα2-t activated focal adhesion kinase (FAK), an important kinase for cancer cell evasion of apoptosis. Conversely, treatment with MATα2 neutralizing antibody inhibited FAK and induced apoptosis. Conclusions CRC cells secrete both MATα2 within EVs and free MATα2-t. EV-MATα2 can be internalized and act as a transcription factor to lower hepatocytes’ MAT1A, the major defense against CRLM, while promoting CRC oncogenicity. Freely released MATα2-t acts as a ligand in an autocrine fashion to activate FAK, which is essential for CRC survival. Taken together, secreted MATα2 plays an essential role in promoting CRLM.

Year:

2025

Introduction: Breast cancer is the second most common cancer among women, and excessive alcohol consumption is a well-established risk factor for various cancers, including breast cancer. Even moderate alcohol consumption (one drink per day) increases breast cancer risk by 10% compared to non-drinking women. The STAR-related lipid transfer domain-containing protein 10 (StarD10), a phosphoprotein, is overexpressed in 35-40% of primary human breast cancers and interacts with the ErbB2 signalling pathway. Our recent studies demonstrated that ethanol administration promotes StarD10 dephosphorylation and increases its activity, as well as enhances ErbB2 expression, which is strongly correlated with increased cell malignancy and aggressiveness. However, the precise role of StarD10 as a subcellular lipid transporter in the regulation of ErbB2 signalling remains unclear. This study aimed to elucidate ethanol-induced changes in StarD10 activity, with the inhibition of its phosphorylation being a potential target for mitigating alcohol-induced breast cancer progression. Materials and Methods: To identify specific phosphorylation sites, phospho-peptide mapping of StarD10 from MCF-7 and SKBR-3 cells was performed. The identified phosphorylation site in StarD10 was further validated by western blot and co-immunoprecipitation studies. A lipid overlay assay was performed to assess StarD10 binding to phospholipids. Results: Phospho-peptide mapping identified threonine 288 (T288) as a specific phosphorylation site, regulated by casein kinase 1α (CK1α). Silencing CK1α blocked StarD10 phosphorylation, mimicking the dephosphorylation effects induced by ethanol. Lipid overlay assay demonstrated that StarD10 binds to a range of phospholipids. We found the interaction of StarD10 with PI(3)P, PI(4)P, PI(5)P, PI(3, 4)P2, PI(3, 5)P2, PI(4, 5)P2, PI(3, 4, 5)P2 in both MCF-7 and SKBR-3 cells. PP2A and PP1, serine/threonine phosphatases regulate protein function by dephosphorylation impacting in several critical cellular pathways. We found that treatment with okadaic acid (a PP2A inhibitor) and calyculin A (a PP1/PP2A inhibitor) blocked ethanol-induced StarD10 dephosphorylation in both MCF-7 and SKBR-3 cells. Also, this treatment inhibited the membrane fluidity as compared to ethanol. It suggests a regulatory role of PP1/PP2A in the StarD10 function. Conclusions: The role of phosphorylated StarD10 in alcohol-induced breast cancer progression is mediated by the phosphorylation of T288 by CK1α. PP1/PP2A acts as a positive regulator of StarD10 activity, further implicating these phosphatases in the progression of ethanol-induced breast cancer. Acknowledgments: R01 AA030576 (NIAAA), Role of StAR-related lipid transfer protein 10 in alcohol-induced breast cancer progression. Citation Format: Manisha Dagar, Andrea Floris, Youngyi Lim, Swati Chandla, Monica Justo, Nirmala Mavila, Komal Ramani, Maria Lauda Tomasi. Phosphorylation of StarD10 advances alcohol induced breast cancer progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 188.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (7)

Avradip Chatterjee

Assistant Professor

The University of Texas Rio Grande Valley

UNITED STATES
View details

DuoYao Cao

Cedars-Sinai Medical Center

UNITED STATES
View details

Michitaka Matsuda

Senior Researcher

National Center For Global Health and Medicine

JAPAN
View details

Ramachandran Murali

Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Shelly Lu

Director, Karsh Division of Gastroenterology and Hepatology

Cedars-Sinai Medical Center

UNITED STATES
View details

Edwin Posadas

Associate Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Sungyong You

Professor

Cedars-Sinai Medical Center

UNITED STATES
View details